COMPOSITION:
Each LuciMava capsule contains Mavacamten ………………….2.5mg.
INDICATIONS
LuciMava is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
DOSAGE AND USE:
The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily.Refer the full Prescribing information for detail instructions.
Capsules should be swallowed whole & not chewed or crushed.
STORAGE:
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS:
Keep medicine out of reach of Children. Do not administer LuciMava during Pregnancy and Lactation.
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/mavacamten/
Related News
-
RASONQUE™ (Daraxonrasib) Clinical Trials, Distribution & Value in Precision Oncology
Clinical Trials of RASONQUE™ (Daraxonrasib) The clinical development of RASONQUE™ (Daraxonrasib) has…
2026-10-05
-
RASONQUE™(Daraxonrasib): Dosage Instructions, Side Effects, FAQ & Myths
How to Take RASONQUE™ (Daraxonrasib) Safely and Effectively Take it exactly as…
2026-10-03
-
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview When Every…
2026-10-01
-
Understanding ATTR-CM: A Patient-Friendly Guide to Transthyretin Amyloidosis Cardiomyopathy
1. Experience: What Living with ATTR-CM Can Feel Like Symptoms of ATTR-CM…
2026-09-04
-
LuciOdevi FAQs, Myths, Clinical‑Trial Data & Medication Distribution Guide | Lucius Pharmaceuticals
Frequently Asked Questions About LuciOdevi Q1. What is LuciOdevi?A: LuciOdevi is an…
2026-08-14
-
Unveiling New Possibilities in the Treatment of Cholestatic Liver Disorders: LuciOdevi 400mcg Developed by Lucius Pharmaceuticals
Introduction Cholestatic liver disorders cover a broad, hard‑to‑treat group of hepatobiliary illnesses…
2026-08-11



